Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  REGENERATIVE MEDICINE
A Global Strategic Business Report

This report analyzes the worldwide markets for Regenerative Medicine in Millions of US$. The report provides separate comprehensive analytics for the US, Japan, and Europe. Annual forecasts are provided for each region for the period of 2003 through 2015. The report profiles 106 companies including many key and niche players worldwide such as BioVest International, Inc., Curis, Inc., Cytori Therapeutics, Inc., DeveloGen AG, Forticell Bioscience, Inc., Geron Corporation, Human Genome Sciences, Inc., IsoTis, Inc., Kiadis Pharma B.V., LifeCell Corporation, Osiris Therapeutics, Inc., Tepha Inc., and TiGenix N.V. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1241  PAGES:    383
PRICE:    $3950  DATE:       April 2008
COMPANIES:  106  MARKET DATA TABLES:   122
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  REGENERATIVE MEDICINE (Complete Report) Pages : 383   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS3$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
II. EXECUTIVE SUMMARY53$2250
  1. Industry Overview.....II-111 $800  
   Regenerative Medicine - the Past, the Present, & the Future.....II-11$100
   Another Revolution in the Making?.....II-2
Conventional Chemical Medicine Vs Regenerative Medicine.....II-2
1$100
   The Need for Regenerative Medicine.....II-3
Regenerative Medicine Throws in Several New Therapies.....II-3
What’s in Store?.....II-3
Regenerative Medicine to Arrest Ageing.....II-3
1$100
   Thriving on an Aging World Population.....II-4
Faster Healing Process.....II-4
Regenerative Medicine to Overcome Donor Organs Shortage.....II-4
1$100
   Possible Scenarios.....II-5
Stem Cell Research – Not Just Another Medical Advancement.....II-5
1$100
   Key Issues At Play.....II-6
Market Potential.....II-6
Regenerative Medicine in Bone and Joint Applications.....II-6
US Corners a Lion’s Share.....II-6
Growth Drivers.....II-6
1$100
   Trends & Issues.....II-7
Biomaterials Sought After in Regenerative Medicine.....II-7
Upbeat Market for Cell-based Tissue Engineering.....II-7
1$100
   Progenitor Cell Therapy to Witness No Holds Barred Growth.....II-8
Players Embrace Automation in Production Facilities.....II-8
1$100
   Contract Manufacturing, a Growing Sector.....II-9
Investors Wary of Funding Regenerative Medicine.....II-9
Regenerative Medicine Field Lags Behind due to Segregated Focus.....II-9
1$100
   Challenges to Be Encountered by Tissue Engineering Companies.....II-10
Activity in the Field of Regenerative Medicine.....II-10
2$200
  2. Product Overview.....II-1210 $700  
   Regenerative Medicine Advances in Four Phases.....II-12
Human Substances.....II-12
Tissue Engineering.....II-12
Therapeutic Cloning.....II-12
Nanotechnology-Driven Biomaterials.....II-12
Types of Regenerative Medicine.....II-12
1$100
   Type I – Regenerative Medicine.....II-13
Human Proteins and Genes are Drugs in Regenerative Medicine.....II-13
Type-2 Regenerative Medicine.....II-13
Therapies Based on Human Cells and Tissues.....II-13
2$200
   Type-3 Regenerative Medicine.....II-15
Based on Embryonic Stem Cells.....II-15
1$100
   The Opponents of the ESC Theory.....II-16
Embryonic Stem Cells – Shortcomings.....II-16
1$100
   Type-4 Regenerative Medicine.....II-17
Based on Novel Materials / Material Science Advancements.....II-17
1$100
   Overview of Major Regenerative Medicine Techniques.....II-18
Natural Regenerative Proteins.....II-18
Tissue Engineering Capable of Culturing Replacement Organs.....II-18
1$100
   All About Stem Cells.....II-19
Adult Stem Cells.....II-19
Adult Stem Cell Research Eludes Ethical Dispute.....II-19
hESC – Highly Capable of Differentiating and Multiplying.....II-19
1$100
   Stem Cell Research in Development of Regenerative Medicine.....II-20
Neural Stem Cell to Restore Memory Functioning.....II-20
Pancreatic Islet Cells to Control Blood Sugar in Diabetics.....II-20
1$100
   Therapeutic Cloning to Cure Parkinson’s.....II-21
1$100
  3. Regulatory Environment.....II-221 $100  
   Regulatory Norms Governing ES Cell Research.....II-22
Milestones in the Human Embryonic Stem Cell Research: 2001.....II-22
Legality of ES Cell Use in Major Developed Nations.....II-22
1$100
  4. Technological Innovations / Breakthroughs.....II-235 $500  
   Celprogen Launches 11 Cancer Stem Cells .....II-23
Biovest International Launches AutovaxID™.....II-23
Stelic Institute Announces New Treatment Method for Acute Liver Failure.....II-23
1$100
   TissueGene Initiates Phase 1 Clinical Trials for TG-C.....II-24
ISTO Announces FDA’s IND Approval for Neocartilage Graft.....II-24
Cook Biotech Introduces Surgisis® AFP™ Anal Fistula Plug.....II-24
Korean Scientists Make a Major Breakthrough in Stem Cell Lines.....II-24
1$100
   Japanese Researchers Regenerate Jaw Bone.....II-25
Geron Researchers Differentiate Hepatocytes from hESCs.....II-25
Geron Demonstrates Potential of hESCs in Treatment of Parkinson’s disease.....II-25
1$100
   Geron Researches Cardiomyocytes for Heart Disease.....II-26
Endovasc Announces New Findings at Texas Heart Institute Research.....II-26
Geron and Celera Genomics Complete Characterization of Active Genes in hESCs.....II-26
1$100
   Rockefeller University Develops Solution for Maintaining Plupotency in hESCs.....II-27
1$100
  5. Recent Industry Activity.....II-2817 $900  
   Cytori and Green Hospital Supply Ink Strategic Equity Deal.....II-28
RNL Bio Establishes Research Unit at Newcastle University.....II-28
Tengion Begins Third Phase II Clinical Trial of Neo-Bladder Augment™.....II-28
Organogenesis Signs MoU with NTEC.....II-28
1$100
   BioTime Establishes New Stem Cell Division.....II-29
Integra Life Sciences Acquires IsoTis, Inc......II-29
NovaThera and Gamida Join Hands for Developing Cell Therapeutics for Lung
  Regeneration.....II-29
1$100
   Tigenix Teams Up With Fidea to Develop Biological Joint Implants.....II-30
Scotland Plans to Build Center for Regenerative Medicine in Edinburgh.....II-30
1$100
   Celmed BioSciences Merges with Kiadis.....II-31
Bayer Acquires Schering AG.....II-31
Genentech Files IND Application with FDA.....II-31
National Stem Cell Holding and Azurel Merge.....II-31
StemCells and Stem Cell Therapeutics in Licensing Agreement.....II-31
1$100
   co.don Signs Distribution Agreement with Austrian Company.....II-32
Olympus to Increase Investment in Olympus-Cytori, Inc......II-32
Geron and University of Edinburgh in Collaboration for Development of hESCs.....II-32
Ortho-McNeil Acquires ColBar LifeScience.....II-32
1$100
   CCMB to Establish Research Center for Regenerative Medicine.....II-33
Cambrex and Cytori Therapeutics in Strategic Alliance.....II-33
co.don Signs Distribution Agreement with XMEDICA.....II-33
NCRM Signs MoU with Eye Hospital for Occular Research.....II-33
1$100
   Theregen Receives Funding from Sanderling Ventures.....II-34
Musculoskeletal Transplant Foundation Signs Research and Investment Agreements with
  ProChon Biotech .....II-34
Olympus and Cytori Therapeutics Establish Olympus-Cytori, Inc......II-34
1$100
   StemCo Biomedical is now Aldagen, Inc......II-35
Healtheuniverse Establishes R&D Base in Singapore.....II-35
BioMimetic Receives FDA Approval for GEM 21S®.....II-35
1$100
   Gambro and Nephrogen in Research Partnership.....II-36
UC-Berkley Bags US$ 2.5 Million Grant from CIRM.....II-36
MacroPore Biosurgery Receives US$ 11 Million through Equity Placement.....II-36
1$100
   World’s third Largest Laboratory for Regenerative Medicine.....II-37
Ortec Forms a Joint Venture with HAPTO.....II-37
Curis Extends Agreement with Genentech.....II-37
Curis Strikes a Deal with Genentech.....II-37
Curis Collaborates with Wyeth Pharmaceuticals.....II-37
co.don Strikes a Deal with Bioengi Ltd.....II-37
StemCells Licenses Stem Cell Technology to ReNeuron.....II-37
1$100
   Osiris Receives FDA Approval to Commence Stem Cell Trial for Knee Repair.....II-38
Geron Corporation and BRC Establish TA Therapeutics Limited.....II-38
Celmed BioSciences Pockets NewBiotics.....II-38
Celmed BioSciences Collaborates with Gambro BCT.....II-38
Ortec Collaborates with ESI.....II-38
1$100
   BMPI in Alliance with Luitpold Pharmaceuticals.....II-39
BioVest International Enters into a Supply Agreement with Bioventix.....II-39
Geron Inks Two Licensing Agreements with Revivicor.....II-39
Geron Enters into a Licensing Agreement with P&G.....II-39
Roslin Institute, Geron, CXR Strike a Deal.....II-39
1$100
   Geron Signs a Licensing Agreement with Xcellsyz.....II-40
Geron Inks a Pact with Merix.....II-40
Agreement between HGSI and GlaxoSmithKline.....II-40
MacroPore Biosurgery Sells off Bioresorbable Thin Film Product Line.....II-40
Jenapharm Divests Therapeutics Business.....II-40
1$100
   Celmed BioSciences Divests Celmed USA.....II-41
Schering Extends Research Facility in Japan.....II-41
Stem Cell Research Gets Approval in California.....II-41
Accentia Acquires Majority Stake in BioVest.....II-41
DeveloGen Merges with Peptor.....II-41
DeveloGen Partners with Evotec OAI.....II-41
1$100
   LifeCell Collaborates with NSCC.....II-42
LifeCell Corporation Accords with SHO.....II-42
Osiris Enters into a Licensing Agreement with JCR.....II-42
TiGenix Inks a Pact with IQL.....II-42
BioVest International Signs an Agreement with BioE, Inc.....II-42
1$100
   PPL Therapeutics Divests Regenerative Medicine Business.....II-43
Osiris Bags EU Patent for Matter Composition in Adult, Human MSC.....II-43
J-TEC and Nagoya University Develop Cell Culture System.....II-43
Marubeni Takes a Minor Stake in GBS.....II-43
Tepha Develops New Biomaterials for Regenerative Medicine.....II-43
1$100
   Gunze Inaugurates Regenerative Medicine Research Facility.....II-44
Geron Corporation and Exeter Life Sciences Establish stART Licensing, Inc.....II-44
Cambrex Establishes New Facility to Manufacture Cell Therapy.....II-44
1$100
  6. Focus on Select Global Players.....II-457 $700  
   BioVest International, Inc. (US).....II-45
Curis, Inc. (US).....II-45
1$100
   Cytori Therapeutics, Inc. (US).....II-46
DeveloGen AG (Germany).....II-46
1$100
   Forticell Bioscience, Inc. (US) .....II-47
Geron Corporation (US).....II-47
1$100
   Human Genome Sciences, Inc. (US).....II-48
IsoTis, Inc. (US) .....II-48
Kiadis Pharma B.V. .....II-48
1$100
   LifeCell Corporation (US).....II-49
Osiris Therapeutics, Inc. (US).....II-49
1$100
   Tepha Inc. (US).....II-50
TiGenix N.V. (Belgium).....II-50
2$200
  7. Global Market Perspective.....II-52   
   Table 1: World Recent Past, Current & Future Market Analysis for Regenerative Medicine Products for Bone and Joint Applications by Geographic Region – US, Japan and Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....II-52

Table 2: World Long-term Projections for Regenerative Medicine Products for Bone and Joint Applications by Geographic Region – US, Japan and Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-52
1$300
   Table 3: World 8-Year Perspective for Regenerative Medicine Products for Bone and Joint Applications by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan and Europe for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-531$300
III. MARKET45$1950
  1. The United States.....III-123 $1025  
   A. Market Analysis.....III-1
Market Potential.....III-1
Regenerative Medicine in Bone and Joint Applications.....III-1
Regenerative Therapy – Best Fit for Joint Problems.....III-1
1$75
   Millions of American Patients Put their Hope in Stem Cell Research.....III-2
Table 4: Prevalence of Various Diseases in the US.....III-2
1$150
   US Witnesses Mixed Response for Government Support for hESC Research.....III-3
CBI’s Human Tissue Products for Treating Liver Failure and Diabetes.....III-3
1$75
   Market for Liver and Pancreas Transplantation.....III-4
Implantable Regenerative Products Take Over Sports Medicine.....III-4
Key Players.....III-4
BioVest International, Inc......III-4
1$75
   Curis, Inc......III-5
Cytori Therapeutics, Inc......III-5
1$75
   Geron Corporation.....III-6
Human Genome Sciences, Inc......III-6
1$75
   IsoTis, Inc. .....III-7
Osiris Therapeutics, Inc......III-7
Revivicor, Inc.......III-7
1$75
   Tepha Inc......III-8
Other Key Players & Activities.....III-8
2$150
   Technological Developments.....III-103$225
   Strategic Developments.....III-1310$625
   B. Market Analytics.....III-23
Table 5: US Recent Past, Current & Future Analysis for Regenerative Medicine Products for Bone and Joint Applications – Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-23

Table 6: US Long-Term projections for Regenerative Medicine Products for Bone and Joint Applications – Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-23
1$150
  2. Japan.....III-246 $425  
   A. Market Analysis.....III-24
Market Potential.....III-24
Research Activity in Regenerative Medicine Field.....III-24
More Companies Eye the Regenerative Medicine Potential.....III-24
1$75
   Competition Heats up Behind Closed Doors.....III-25
Japanese Firms Need to Catch Up with US and European Competitors.....III-25
Science Ministry Rolls Out Regenerative Medicine Project.....III-25
1$75
   Regenerative Medicine Exempted from Ban on Human Cloning.....III-26
Technological Developments.....III-26
1$75
   Strategic Developments.....III-27
Developments in Recent Past .....III-27
1$75
   B. Market Analytics.....III-28
Table 7: Japanese Recent Past, Current & Future Analysis for Regenerative Medicine Products for Bone and Joint Applications – Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-28
1$150
   Table 8: Japanese Long-Term projections for Regenerative Medicine Products for Bone and Joint Applications – Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-29
1$150
  3. Europe.....III-307 $375  
   A. Market Analysis.....III-30
Germany.....III-30
Key Players.....III-30
co.don AG.....III-30
DeveloGen AG.....III-30
1$75
   United Kingdom.....III-31
Belgium.....III-31
Select Player......III-31
TiGenix N.V. .....III-31
1$75
   Strategic Developments.....III-324$300
   B. Market Analytics.....III-36
Table 9: European Recent Past, Current & Future Analysis for Regenerative Medicine Products for Bone and Joint Applications – Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-36

Table 10: European Long-Term projections for Regenerative Medicine Products for Bone and Joint Applications – Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-36
1$150
  4. Review of Regenerative Medicine in Other Geographic Markets.....III-379 $675  
   Review of Regenerative Medicine in Other Geographic Markets.....III-37
4a. Canada.....III-37
University of Toronto – Spearheading Regenerative Medicine Research.....III-37
Strategic Developments.....III-37
2$150
   4b. Asia-Pacific.....III-39
China.....III-39
Substantial Government Support.....III-39
India.....III-39
CSIR- Leading the way in Regenerative Medicine Research.....III-39
High Growth Opportunities.....III-39
1$75
   Australia.....III-40
Key Player.....III-40
Stem Cell Sciences.....III-40
South Korea.....III-40
Malaysia.....III-40
1$75
   Singapore.....III-41
Strategic Developments.....III-41
3$225
   4c. Rest of World.....III-44
Argentina.....III-44
Israel .....III-44
Select Major Players.....III-44
Colbar R&D Ltd......III-44
ProChon Biotech Ltd.......III-44
1$75
   South Africa.....III-45
Strategic Development.....III-45
1$75
IV. COMPETITIVE LANDSCAPE 270$995
  
Total Companies Profiled: 106 (including Divisions/Subsidiaries - 109 )

Region/Country                 Players


The United States                 59
Canada                             2
Japan                             12
Europe                            20
     Germany                       6
     The United Kingdom            6
     Italy                         1
     Rest of Europe                7
Asia-Pacific (Excluding Japan)     8
Middle-East                        3
Latin America                      1
Africa                             4
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2010, Global Industry Analysts, Inc., USA.